logo
New Survey Shows Physician Appointment Wait Times Surge: 19% Since 2022, 48% Since 2004

New Survey Shows Physician Appointment Wait Times Surge: 19% Since 2022, 48% Since 2004

DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- The time required to schedule a physician appointment in 15 major metropolitan areas has increased by 19% since 2022 and by 48% since 2004, according to a new survey conducted by AMN Healthcare, the nation's leading healthcare workforce solutions company.
The 2025 Survey of Physician Appointment Wait Times reveals that it now takes an average of 31 days to schedule a physician appointment in 15 of the largest metropolitan areas in the United States. This is an increase from 26 days in 2022, the last year the survey was conducted, and from 21 days in 2004, the first year the survey was conducted.
'Average physician appointment wait times are the longest they have been since we began conducting the survey in 2004,' said Leah Grant, president of AMN Healthcare's Physician Solutions division (formerly known as Merritt Hawkins). 'Longer physician appointment wait times are a significant indicator that the nation is experiencing a growing shortage of physicians.'
The survey tracked average new patient physician appointment wait times in six specialties: obstetrics/gynecology, cardiology, orthopedic surgery, dermatology, gastroenterology, and family medicine. Average physician appointment wait times in the six specialties include:
Average physician appointment wait times for all specialties vary by metropolitan area. Boston has the longest average physician appointment wait time at 65 days, while Atlanta has the shortest at 12 days.
The metropolitan areas included in the survey have some of the highest physician-to-population ratios in the country. According to Grant, if patients are having difficulty scheduling appointments in these highly populated areas, it can be assumed that access to physicians may be even more problematic in areas with fewer physicians.
'It's a sobering sign for the rest of the country when even patients in large cities must wait weeks to see a physician,' Grant said.
Physician appointment wait times can vary widely depending on the specialty and metropolitan area. Wait times can range from as short as one day to as long as 291 days for a dermatology appointment in Portland, Oregon, as long as 231 days for an obstetrics/gynecology appointment in Boston, as long as 208 days for a gastroenterology appointment in Detroit, and as long as 175 days for a cardiology appointment in Washington, D.C.
Physician Medicare and Medicaid Acceptance Rates
The survey also indicates that 82% of physicians in the 15 major metropolitan markets accept Medicare as a form of payment. Boston has the highest number of physicians accepting Medicare at 94%, while Atlanta has the lowest at 68%.
By contrast, only 53% of physicians in the 15 metropolitan areas accept Medicaid as a form of payment. Detroit has the highest number of physicians accepting Medicaid at 85%, while New York has the lowest at 28%.
'The type of health insurance patients have may impact their access to physicians,' said Leah Grant. 'While Medicare is widely accepted by physicians, Medicaid is less so.'
The survey includes data from 1,391 physician offices located in 15 metropolitan areas, including Atlanta, Boston, Dallas, Denver, Detroit, Houston, Los Angeles, Miami, Minnesota, New York City, Philadelphia, Portland, San Diego, Seattle, and Washington, D.C. To view AMN Healthcare's 2025 Survey of Physician Appointment Wait Times visit https://online.flippingbook.com/view/83050962/.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

Yahoo

time2 hours ago

  • Yahoo

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@

3 Reasons Why Coca-Cola Is Still a Top Dividend Stock for Generating Passive Income
3 Reasons Why Coca-Cola Is Still a Top Dividend Stock for Generating Passive Income

Yahoo

time2 hours ago

  • Yahoo

3 Reasons Why Coca-Cola Is Still a Top Dividend Stock for Generating Passive Income

Key Points Coke continues to generate organic growth despite a highly challenging operating environment. The company is adapting to changing consumer preferences and regulatory pressure by offering Coke made with U.S. cane sugar instead of corn syrup. Coke has a growing and affordable dividend with a competitive yield. 10 stocks we like better than Coca-Cola › Some top stocks are known for their growth potential, while others are recognized for their predictability. Coca-Cola (NYSE: KO) is in that second camp. The company isn't perfect, and its results have been disappointing in some periods. But through it all, one constant that investors have been able to count on is Coke's rock-solid dividend. Coke is unique because it has a high yield at 3% and it has an extensive track record of increasing its payout. It has done so for 63 consecutive years, earning it a spot on the list of Dividend Kings. Here's why Coke remains a great buy for investors looking to boost their passive income. 1. Delivering solid results Coke reported a good second quarter on July 22. The company grew organic revenue by 5%, comparable earnings per share (EPS) by 4%, and comparable operating margins rose to 34.7% versus 32.8% for the second quarter of 2024. For the full year, Coke expects organic revenue growth of 5% to 6%, comparable currency-neutral EPS of 8%, and comparable EPS of $2.88. So currency headwinds are really throwing a wrench in Coke's results and detracting from the strength of the underlying business. Coke's resilient results didn't get a big reaction from Wall Street, but that may be because Coke is up around 11% on the year, which is slightly better than the gain for the S&P 500 (SNPINDEX: ^GSPC). Coke has been a standout in what has otherwise been a challenging consumer staples sector -- especially for packaged food and beverage and snack companies. Many food and beverage stocks are at multiyear, if not multidecade, lows. Inflation and relatively high interest rates have been hitting consumer demand hard for everyday household goods. When the cost of these goods go up, it affects all consumers, but especially those with less discretionary income. Another challenge is changes in consumer preferences. Some consumers are shifting their buying behavior toward healthier options, characterized by lower sugar content, better ingredients, and improved nutrition. These trends were reflected in Coke's latest results, which highlighted volume growth in Coca-Cola Zero Sugar, Diet Coke, Fanta, Fairlife, BodyArmor, and Powerade. For years now, Coke has been seeing excellent growth in zero sugar and diet versions of its flagship Coca-Cola products -- a sign that investment in these labels is paying off. 2. Adapting to the times The Trump administration's Make America Healthy Again Commission is pressuring food and beverage companies to phase out petroleum-based synthetic dyes and replace artificial ingredients with natural ingredients. On its latest earnings call, Coke said that it plans to expand its Trademark Coca-Cola product range to include U.S. cane sugar this fall. In the U.S., Coke uses high-fructose corn syrup as its primary sweetener because it is cost-effective. But Coke made in Mexico typically uses cane sugar, which is why some consumers tend to go out of their way to buy this product version. The decision to make Coke with cane sugar in the U.S. may have garnered a negative reaction if announced years ago, but the time is right to make this change. Coke's standout brands in recent years have generally been the healthier options in its portfolio. It has had resounding success growing Topo Chico since it acquired the brand in 2017. Similarly, its dairy brand Fairlife (acquired in 2020) has been a value add for the company. Not only are these brands doing well, but they also diversify Coke away from a majority soda lineup toward other options, which makes the company better positioned to unlock earnings growth from a diversified revenue stream. 3. A growing and affordable dividend Money isn't created out of thin air. For a company to consistently grow its dividend and thus incur a larger dividend expense, it must grow its earnings. Coke's earnings growth hasn't been great in recent years, but that's mostly because it has been making significant changes to its brand lineup and addressing the aforementioned challenges. However, the growth has been sufficient for Coke to continue increasing its dividend. Coca-Cola pays a $0.51 per share quarterly dividend, or $2.04 per year. If Coke hits its adjusted EPS guidance of 3%, earnings will be $2.97 in 2025 -- meaning that Coke can afford to grow its dividend without impacting its financial health or taking away cash that could otherwise be reinvested in the business. Coke also has a reasonable valuation. Based on the share price of $69.17 at the time of this writing and $2.97 in 2025 earnings, Coke would have a price-to-earnings ratio of 23.3. It's not a bargain-bin price for a low-growth dividend stock. And there are plenty of better deals available for investors seeking a superior value. However, Coke arguably deserves this valuation because the dividend is so reliable, and the company continues to generate organic growth and pricing power at a time when many of its peers are struggling. A potential centerpiece of a passive income portfolio Coke's brand lineup, high-margin business, and willingness to adapt to changes in consumer preferences make the company a worthy foundational holding for income investors. The shift from corn syrup to cane sugar in the U.S. may lead to higher costs in the near term, but the move could pay off if it increases sales volumes. Coke continues to demonstrate why it is the industry leader across numerous non-alcoholic beverage categories, and why the stock remains a plug-and-play option for income investors to add to their portfolios. Do the experts think Coca-Cola is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Coca-Cola make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,041% vs. just 183% for the S&P — that is beating the market by 858.71%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Daniel Foelber has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 3 Reasons Why Coca-Cola Is Still a Top Dividend Stock for Generating Passive Income was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Boeing Q2 results beat expectations as planemaker slashes costs
Boeing Q2 results beat expectations as planemaker slashes costs

Yahoo

time2 hours ago

  • Yahoo

Boeing Q2 results beat expectations as planemaker slashes costs

Boeing (BA) reported second quarter earnings on Tuesday that topped expectations, and stemmed the tide of cash burn that plagued Boeing since early last year as CEO Kelly Ortberg to continues his turnaround of the beleaguered jet maker. Boeing reported revenue of $22.7 billion vs. $21.68 billion estimated per Bloomberg consensus, a 35% jump compared to a year ago, when the company was mired in a production slowdown stemming from the door plug blowout of an Alaska Airlines 737 Max jet. Boeing posted adjusted EPS, or core loss per share, of $1.24 vs $1.40 estimated, with an operating loss of $176 milloin vs $161.1 million estimated. Most importantly, Boeing's free cash flow, or cash burn rate was slashed to just $200 million in Q2, a massive improvement to the $2.3 billion seen last quarter, and the $4.3 billion cash burn seen a year ago. "With the start of the second half of the year, we are moving in the right direction and ahead of where I thought we would be in our recovery. If we continue to tackle the important work ahead of us and focus on safety, quality and stability, we can navigate the dynamic global environment and make 2025 our turnaround year," CEO Kelly Ortberg said in a memo to employees. Boeing stock was up over 2% in pre-market trading. Read more: Live coverage of corporate earnings Boeing, once the world's largest plane maker, is in the process of turning its business around following a disastrous 2024, which began with the aforementioned door plug blowout in January. Issues with its supplier Spirit AeroSystems (SPR) and various whistleblower complaints stemming from both production of the 737 Max jet and widebody 787 Dreamliner eventually cost then-CEO Dave Calhoun his job, with Kelly Ortberg named the new CEO in late July and starting on Aug. 8. Ortberg began his turnaround plan deliberately, slowing production of Boeing's jets to hammer out production issues and slowly boosting production in close conjunction with FAA regulators. Earlier this month, Boeing announced that commercial deliveries hit 150 jets vs. 130 delivered in the first quarter and 92 delivered in the year-ago quarter. Of Q2 deliveries, 102 were 737 Max jets (compared to 69 delivered a year ago), 24 787s (nine last year), 13 777s (seven last year), and nine 767s (six last year). As for cranking up its 737 Max production, Ortberg said in late May that Boeing's goal was to reach a rate of 42 a month by midyear and be in a position at the end of the year to review readiness for a rate of 47 a month. Boeing said 737 production hit 38 planes per month in Q2. "Boeing continues to show great progress, but the ramp-up may be more gradual than our prior view," William Blair analyst Louie DiPalma wrote shortly after Ortberg's comments. "Our earlier note indicated that a 47 monthly production rate was possible by the end of 2025. Our new view is that the 47 aircraft per month target is more likely in mid-2026." Boeing faced another crisis in June when an Air India 787 Dreamliner crashed shortly after takeoff from Ahmedabad Airport. Initial reports, however, suggest pilot error may have caused the crash, with the engine fuel control switches moved to the "cut-off" position. Investigators are still trying to determine why that was the case. However, President Trump's announcement of a trade deal with the EU is seen as a positive for both the autos and aviation sectors, as there was an expectation that the EU would have retaliated with punitive tariffs on aviation products and parts coming from the US. Pras Subramanian is the lead auto reporter for Yahoo Finance. You can follow him on X and on Instagram. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store